Cardiac Marker Testing Market

The cardiac marker testing market is estimated to be valued at USD 5.07 billion in 2025 and USD 5.54 billion in 2026, and is expected to reach USD 9.06 billion by 2031. The growth of the cardiac marker testing market is mainly driven by the rising incidence of CVDs and the emphasis on early detection of cardiac disorders. The market is driven by several key factors, such as the rising incidence of cardiac emergencies, the increase in point-of-care testing, and the growth of healthcare infrastructure in developing countries. Moreover, improvements in high-sensitivity tests, along with increased automation in diagnostic labs, are contributing to market growth.

In November 2025, the US Food and Drug Administration granted 510(k) clearance to QuidelOrtho Corporation for its VITROS high-sensitivity Troponin I (hs Troponin I) Reagent Pack, an assay designed for the quantitative measurement of cardiac troponin I (cTnI) in human plasma (heparin), supporting the diagnosis of myocardial infarction and enabling more accurate and timely decision-making.

To know about the assumptions considered for the study download the pdf brochure

In May 2024, F. Hoffmann-La Roche AG (Switzerland) was granted Device Designation by the U.S. Food and Drug Administration for its blood test, which measures lipoprotein(a) levels, a significant marker of hereditary risk of cardiovascular disease.

Some of the major players in the cardiac marker testing market with significant global presence include F. Hoffmann-La Roche (Switzerland), Abbott Laboratories (US), Becton, Dickinson and Company (US), Siemens Healthineers (Germany), and Bio-Rad Laboratories (US), among others. The companies have followed a number of strategies, such as product launches and expansions, to strengthen their global presence and improve their market shares in the global cardiac marker testing market. The strategies have helped companies gain a presence in different regions of the world by providing high-class cardiac biomarker testing solutions and services.

F. Hoffmann-La Roche (Switzerland) is a significant player in the global cardiac marker testing market, due to its strong presence in the in vitro diagnostics segment and its wide range of cardiac biomarker testing solutions. The company focuses on continuous innovation through significant investments in R&D to provide high-sensitivity, integrated diagnostic solutions. Besides, Roche is building partnerships via collaborations and acquisitions to strengthen its technology capabilities and expand its market presence. The company's dedication to providing efficient, simple, and integrated diagnostic solutions, especially in point-of-care diagnostics, will further strengthen its competitive position in the cardiac marker testing market.

Abbott (US) has a strong base in the US market and continues to attempt to expand its presence in emerging markets. The company has a strong product portfolio of cardiac biomarker tests, with some products approved by regulatory authorities such as the US FDA and CE-marked, thereby contributing to its market share. Abbott has been making efficient use of strategic partnerships, acquisitions, and collaborations to enhance its product offerings and geographical presence. In addition, Abbott's efforts to strengthen its position in the cardiac marker testing market will be driven by ongoing enhancements to its research and development capabilities, a strong pipeline, and clinical validation of its assays.

Market Ranking

F. Hoffmann-La Roche (Switzerland) holds a dominant share of the cardiac marker testing market due to its wide range of high-sensitivity cardiac biomarker tests and diagnostic platforms. Abbott Laboratories (US) holds a significant share of the cardiac marker testing market due to its advanced immunoassay platforms and widely used point-of-care solutions. Becton, Dickinson and Company (US) further strengthens its foothold in the cardiac marker testing market through its wide range of diagnostic solutions and lab platforms for efficient cardiac marker testing. Similarly, Siemens Healthineers (France) has a significant contribution to the cardiac marker testing market through its reliable immunoassay platforms and high-sensitivity troponin tests for precise cardiac marker testing. Bio-Rad Laboratories also plays a vital role in the cardiac marker testing market through its quality control solutions that enable precise testing.

Related Reports:

Cardiac Marker Testing Market by Product, Biomarker (Troponin, CK-MB, BNP, hs-CRP, Myoglobin), Technology (Chemiluminescence, ELISA), Indication (MI, CHF, Atherosclerosis), Assay Format (Singleplex, Multiplex), Point of Testing - Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]